Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
Knowledge of tumor mutation status is becoming increasingly important for the treatment of cancer, as mutation-specific inhibitors are being developed for clinical use that target only sub-populations of patients with particular tumor genotypes. Melanoma provides a recent example of this paradigm. W...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3335021?pdf=render |
| _version_ | 1817977465024282624 |
|---|---|
| author | Christine M Lovly Kimberly Brown Dahlman Laurel E Fohn Zengliu Su Dora Dias-Santagata Donna J Hicks Donald Hucks Elizabeth Berry Charles Terry MarKeesa Duke Yingjun Su Tammy Sobolik-Delmaire Ann Richmond Mark C Kelley Cindy L Vnencak-Jones A John Iafrate Jeffrey Sosman William Pao |
| author_facet | Christine M Lovly Kimberly Brown Dahlman Laurel E Fohn Zengliu Su Dora Dias-Santagata Donna J Hicks Donald Hucks Elizabeth Berry Charles Terry MarKeesa Duke Yingjun Su Tammy Sobolik-Delmaire Ann Richmond Mark C Kelley Cindy L Vnencak-Jones A John Iafrate Jeffrey Sosman William Pao |
| author_sort | Christine M Lovly |
| collection | DOAJ |
| description | Knowledge of tumor mutation status is becoming increasingly important for the treatment of cancer, as mutation-specific inhibitors are being developed for clinical use that target only sub-populations of patients with particular tumor genotypes. Melanoma provides a recent example of this paradigm. We report here development, validation, and implementation of an assay designed to simultaneously detect 43 common somatic point mutations in 6 genes (BRAF, NRAS, KIT, GNAQ, GNA11, and CTNNB1) potentially relevant to existing and emerging targeted therapies specifically in melanoma.The test utilizes the SNaPshot method (multiplex PCR, multiplex primer extension, and capillary electrophoresis) and can be performed rapidly with high sensitivity (requiring 5-10% mutant allele frequency) and minimal amounts of DNA (10-20 nanograms). The assay was validated using cell lines, fresh-frozen tissue, and formalin-fixed paraffin embedded tissue. Clinical characteristics and the impact on clinical trial enrollment were then assessed for the first 150 melanoma patients whose tumors were genotyped in the Vanderbilt molecular diagnostics lab.Directing this test to a single disease, 90 of 150 (60%) melanomas from sites throughout the body harbored a mutation tested, including 57, 23, 6, 3, and 2 mutations in BRAF, NRAS, GNAQ, KIT, and CTNNB1, respectively. Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively. 23 of 54 (43%) patients with mutation harboring metastatic disease were subsequently enrolled in genotype-driven trials.We present development of a simple mutational profiling screen for clinically relevant mutations in melanoma. Adoption of this genetically-informed approach to the treatment of melanoma has already had an impact on clinical trial enrollment and prioritization of therapy for patients with the disease. |
| first_indexed | 2024-04-13T22:16:48Z |
| format | Article |
| id | doaj.art-c2f35af3ee7c4c6987cfa14245f98a46 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T22:16:48Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-c2f35af3ee7c4c6987cfa14245f98a462022-12-22T02:27:30ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0174e3530910.1371/journal.pone.0035309Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.Christine M LovlyKimberly Brown DahlmanLaurel E FohnZengliu SuDora Dias-SantagataDonna J HicksDonald HucksElizabeth BerryCharles TerryMarKeesa DukeYingjun SuTammy Sobolik-DelmaireAnn RichmondMark C KelleyCindy L Vnencak-JonesA John IafrateJeffrey SosmanWilliam PaoKnowledge of tumor mutation status is becoming increasingly important for the treatment of cancer, as mutation-specific inhibitors are being developed for clinical use that target only sub-populations of patients with particular tumor genotypes. Melanoma provides a recent example of this paradigm. We report here development, validation, and implementation of an assay designed to simultaneously detect 43 common somatic point mutations in 6 genes (BRAF, NRAS, KIT, GNAQ, GNA11, and CTNNB1) potentially relevant to existing and emerging targeted therapies specifically in melanoma.The test utilizes the SNaPshot method (multiplex PCR, multiplex primer extension, and capillary electrophoresis) and can be performed rapidly with high sensitivity (requiring 5-10% mutant allele frequency) and minimal amounts of DNA (10-20 nanograms). The assay was validated using cell lines, fresh-frozen tissue, and formalin-fixed paraffin embedded tissue. Clinical characteristics and the impact on clinical trial enrollment were then assessed for the first 150 melanoma patients whose tumors were genotyped in the Vanderbilt molecular diagnostics lab.Directing this test to a single disease, 90 of 150 (60%) melanomas from sites throughout the body harbored a mutation tested, including 57, 23, 6, 3, and 2 mutations in BRAF, NRAS, GNAQ, KIT, and CTNNB1, respectively. Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively. 23 of 54 (43%) patients with mutation harboring metastatic disease were subsequently enrolled in genotype-driven trials.We present development of a simple mutational profiling screen for clinically relevant mutations in melanoma. Adoption of this genetically-informed approach to the treatment of melanoma has already had an impact on clinical trial enrollment and prioritization of therapy for patients with the disease.http://europepmc.org/articles/PMC3335021?pdf=render |
| spellingShingle | Christine M Lovly Kimberly Brown Dahlman Laurel E Fohn Zengliu Su Dora Dias-Santagata Donna J Hicks Donald Hucks Elizabeth Berry Charles Terry MarKeesa Duke Yingjun Su Tammy Sobolik-Delmaire Ann Richmond Mark C Kelley Cindy L Vnencak-Jones A John Iafrate Jeffrey Sosman William Pao Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE |
| title | Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. |
| title_full | Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. |
| title_fullStr | Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. |
| title_full_unstemmed | Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. |
| title_short | Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. |
| title_sort | routine multiplex mutational profiling of melanomas enables enrollment in genotype driven therapeutic trials |
| url | http://europepmc.org/articles/PMC3335021?pdf=render |
| work_keys_str_mv | AT christinemlovly routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT kimberlybrowndahlman routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT laurelefohn routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT zengliusu routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT doradiassantagata routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT donnajhicks routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT donaldhucks routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT elizabethberry routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT charlesterry routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT markeesaduke routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT yingjunsu routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT tammysobolikdelmaire routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT annrichmond routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT markckelley routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT cindylvnencakjones routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT ajohniafrate routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT jeffreysosman routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials AT williampao routinemultiplexmutationalprofilingofmelanomasenablesenrollmentingenotypedriventherapeutictrials |